Name | Alliance Pharma |
---|---|
Epic | APH |
Isin | GB0031030819 |
Index | AIM100 AIM350 |
Industry | Pharmaceuticals & Biotechnology |
Latest share price | 45.50p | Net gearing | n/a |
---|---|---|---|
Market capitalisation | £245.96 | Debt ratio | n/a |
Shares in issue | 540.40 | Debt-to-equity ratio | n/a |
P/E ratio | 12.4 | Assets / equity ratio | n/a |
Total dividends per share | 1.776p | Price to book value | n/a |
Dividend yield | 3.4 | ROCE | 16.17 |
Dividend cover | 2.41 | EPS growth | -33 |
Earning per share | 0.17 | 52-week high / low | 29.35p / 47.70p |
Type | Ex-date | Pay-date | Net-dividend |
---|---|---|---|
Final | 2023-06-22 | 2023-07-18 | 1.184p |
Interim | 2022-12-22 | 2023-01-19 | 0.592p |
Final | 2022-06-09 | 2022-07-07 | 1.128p |
Interim | 2021-12-16 | 2022-01-07 | 0.563p |
Final | 2021-06-10 | 2021-07-08 | 1.074p |
Interim | 2020-12-17 | 2021-01-07 | 0.536p |
Interim | 2019-12-19 | 2020-01-10 | 0.536p |
Final | 2019-06-13 | 2019-07-11 | 0.977p |
Interim | 2018-12-20 | 2019-01-10 | 0.487p |
Company name | Alliance Pharma |
---|---|
Address | Avonbridge House, Bath Road, Chippenham, Wiltshire, United Kingdom, SN15 2BB |
Telephone | +44 (0)1249 466966 |
Website | http://www.alliancepharma.co.uk |
Director | Position |
---|---|
Mr Peter Butterfield | CEO |
Mr Andrew Franklin | CFO |
Mr Camillo Pane | Chairman |
Mr Eva-Lotta Sjöstedt | Non-Executive Director |
Mr Richard McKenzie | Non-Executive Director |
Mr Richard Jones | Senior Independent Director |
Mr Kristof Neirynck | Independent Non-Executive Director |
Mr Martin Sutherland | Independent Non-Executive Director |
Mr Jeyan Heper | Chief Operating Officer |
Assets £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
Intangible asssets and goodwill | 421.63 | 413.74 | 412.87 |
Investments and other non-current assets | n/a | n/a | n/a |
Total non-current assets | 431.93 | 422.47 | 431.61 |
Inventory / work in progress | 24.29 | 21.07 | 22.92 |
Trade and other receivables | 49.32 | 30.82 | 25.11 |
Cash and equivalents | 31.71 | 29.06 | 28.9 |
Other current assets and asset held for resale | 0.16 | 0.06 | 0.31 |
Total of all assets | 537.41 | 503.49 | 508.85 |
Liabilities £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Short term liabilities | 47.02 | 40.58 | 30.19 |
Long term liabilities | 202.73 | 180.42 | 197.71 |
Other liabilites / pension etc | n/a | n/a | n/a |
Total of all liabilities | 249.75 | 221 | 227.9 |
Net assets £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Net assets | 287.66 | 282.49 | 280.96 |
Equity £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Share capital | 5.4 | 5.38 | 5.33 |
Minority interests | n/a | n/a | n/a |
Retained earnings | 108.24 | 116.42 | 117.7 |
Share premium account | 151.65 | 151.33 | 150.65 |
Total equity | 287.66 | 282.49 | 280.96 |
Income £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Turnover | n/a | n/a | n/a |
Operating profit | 10.57 | 21.57 | 16.32 |
Pre-tax profit | 5.21 | 18.16 | 13.02 |